Crucell Announces New Award of $110 Million for Paediatric Vaccine Quinvaxem(R) by UNICEF to Support Vaccination Programs in the Developing World LEIDEN, The ...
Leiden, the Netherlands (July 8, 2010) - Dutch biopharmaceutical company Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that Crucell and sanofi pasteur reached an ...
U.S. healthcare giant Johnson & Johnson (NYSE:JNJ) has launched a $2.3 billion bid to takeover vaccine maker Crucell in an effort to catapult itself into the global vaccine market. Through its newly ...
Van Herk Groep has taken note of the announcement of 6 October 2010 that Johnson & Johnson (J&J) and the board of Crucell have reached agreement on J&J making a bid. Van Herk Groep has been a Crucell ...
Leiden, the Netherlands (August 11, 2010) - Dutch biopharmaceutical company Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announces its intention to participate in an ...
* Expects to enter development contracts with governments * Fast-track designation hinges on level of flu virus threat * Technology could cut cost of making antibodies By Aaron Gray-Block AMSTERDAM, ...
LEIDEN, The Netherlands, July 29, 2009 – The US-based PATH Malaria Vaccine Initiative (MVI), the United States Agency for International Development (USAID) Malaria Vaccine Development Program (MVDP), ...
AMSTERDAM, Aug 17 (Reuters) - Dutch biotech group Crucell swung to a second-quarter net profit as it benefited from production problems at one of its key rivals, and it raised its full-year guidance ...
TRENTON, N.J. -- Johnson & Johnson said Wednesday it is buying Holland's Crucell NV for about $2.41 billion, marking the American health care giant's latest effort to gain a big foothold in the ...
U.S. pharmaceutical giant Johnson & Johnson (JNJ) has finally launched its bid for the Dutch vaccine maker Crucell. Through a subsidiary, J&J is offering to buy all the Crucell shares that it doesn't ...
Dutch biotechnology company Crucell has suffered a blow to its near-term product pipeline after calling time on Aerugen, a vaccine candidate for treating bacterial infections in patients with cystic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results